ATE271874T1 - Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen - Google Patents

Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen

Info

Publication number
ATE271874T1
ATE271874T1 AT98908565T AT98908565T ATE271874T1 AT E271874 T1 ATE271874 T1 AT E271874T1 AT 98908565 T AT98908565 T AT 98908565T AT 98908565 T AT98908565 T AT 98908565T AT E271874 T1 ATE271874 T1 AT E271874T1
Authority
AT
Austria
Prior art keywords
inosine
medication
producing
axon growth
cns neurons
Prior art date
Application number
AT98908565T
Other languages
English (en)
Inventor
Larry I Benowitz
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Application granted granted Critical
Publication of ATE271874T1 publication Critical patent/ATE271874T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
AT98908565T 1997-09-02 1998-02-20 Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen ATE271874T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/921,902 US6440455B1 (en) 1997-09-02 1997-09-02 Methods for modulating the axonal outgrowth of central nervous system neurons
PCT/US1998/003001 WO1999011274A1 (en) 1997-09-02 1998-02-20 Use of purine nucleosides for modulating the axonal outgrowth of central nervous system neurons

Publications (1)

Publication Number Publication Date
ATE271874T1 true ATE271874T1 (de) 2004-08-15

Family

ID=25446158

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98908565T ATE271874T1 (de) 1997-09-02 1998-02-20 Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen

Country Status (12)

Country Link
US (8) US6440455B1 (de)
EP (2) EP1009412B1 (de)
JP (1) JP4601816B2 (de)
KR (1) KR100564789B1 (de)
CN (1) CN1286632A (de)
AT (1) ATE271874T1 (de)
AU (1) AU748961B2 (de)
CA (1) CA2302156C (de)
DE (1) DE69825292T2 (de)
NZ (1) NZ503073A (de)
RU (1) RU2212241C2 (de)
WO (1) WO1999011274A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440455B1 (en) 1997-09-02 2002-08-27 Children's Medical Center Corporation Methods for modulating the axonal outgrowth of central nervous system neurons
IL142896A0 (en) * 1998-11-02 2002-04-21 Elan Corp Plc Multiparticulate modified release composition
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
US7582680B1 (en) 1998-11-12 2009-09-01 Purdue Research Foundation Methods and compositions for treating mammalian spinal cord injuries
US7172871B1 (en) * 2000-09-07 2007-02-06 Children's Medical Center Corporation Methods and compositions for modulating axonal outgrowth of central nervous system neurons
FR2814077A1 (fr) * 2000-09-20 2002-03-22 Inst Nat Sante Rech Med Utilisation de modulateurs de recepteurs a l'adenosine pour reguler la fonction des netrines et/ou de leurs recepteurs
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
ES2382899T3 (es) * 2001-04-24 2012-06-14 Purdue Research Foundation Método y composiciones para tratar lesiones en tejido nervioso de mamífero
US7147647B2 (en) * 2002-04-26 2006-12-12 Medtronic, Inc. Sintered titanium tube for the management of spinal cord injury
US20040106896A1 (en) * 2002-11-29 2004-06-03 The Regents Of The University Of California System and method for forming a non-ablative cardiac conduction block
US6904118B2 (en) 2002-07-23 2005-06-07 General Electric Company Method and apparatus for generating a density map using dual-energy CT
US7813473B2 (en) * 2002-07-23 2010-10-12 General Electric Company Method and apparatus for generating temporally interpolated projections
WO2004022039A2 (en) * 2002-09-03 2004-03-18 Neurological Technologies Inc. Use of guanosine or inosine as anti-apoptotic agents in the treatment of i. a. neurodegenerative diseases or injuries at the nervous system
CA2500908A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
US7199110B2 (en) * 2002-12-30 2007-04-03 Purdue Research Foundation Method of treatment for spinal cord injury
US7842232B2 (en) * 2003-05-22 2010-11-30 Elan Pharma International, Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
GB0312844D0 (en) * 2003-06-04 2003-07-09 Paradigm Therapeutics Ltd Use of compounds in medicine
WO2005016359A1 (en) * 2003-08-19 2005-02-24 Neurological Technologies Inc. Method of promoting remyelination
US8912144B2 (en) * 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
US20080113016A1 (en) * 2004-07-26 2008-05-15 Gary Steven Firestein Method for Prevention or Treatment of Inflammatory Disease
US20060104969A1 (en) * 2004-08-16 2006-05-18 Massachusetts Institute Of Technology Compositions and methods for enhancing structural and functional nervous system reorganization and recovery
EP1855651A4 (de) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd Nanopartikelzusammensetzungen heterocyclischer amidderivate
WO2006111348A1 (de) * 2005-04-18 2006-10-26 Abbott Gmbh & Co. Kg Verwendung von heparin und heparinderivaten zur modulation des neuritenwachstum-kontrollierenden nogo-rezeptors
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
AU2007234006A1 (en) * 2006-03-31 2007-10-11 Adenobio N.V. Compositions, methods, and kits using adenosine and inosine in combination for diagnosis and treatment
JP2009543803A (ja) * 2006-07-12 2009-12-10 エラン・ファルマ・インターナショナル・リミテッド モダフィニルのナノ粒子製剤
US8419710B2 (en) * 2006-12-06 2013-04-16 Medtronic, Inc. Methods for infusing fluids via an implantable infusion system
US20080270686A1 (en) * 2007-04-26 2008-10-30 Grannan Michael F Methods and system to cache content on a vehicle
US8133861B2 (en) * 2008-02-29 2012-03-13 Alseres Pharmaceuticals, Inc. Systemic purine administration: modulating axonal outgrowth of central nervous system neurons
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
DK2502623T3 (en) 2008-06-06 2016-07-04 Children's Medical Center Corp Promoting axonregeneration the adult cns by management of protein translation
PH12012501070A1 (en) 2009-12-08 2017-08-23 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
AU2013211939C1 (en) 2012-01-27 2018-06-07 AbbVie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
US20140179741A1 (en) * 2012-10-10 2014-06-26 Massachusetts Institute Of Technology Use of chelators of divalent cations to promote nerve regeneration
WO2014096958A1 (en) * 2012-11-02 2014-06-26 Academisch Medisch Centrum Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders
RU2517117C2 (ru) * 2012-11-26 2014-05-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Казанский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Казанский ГМУ Минздравсоцразвития России) Способ стимулирования регенерации нерва с помощью наноструктурированного матрикса и генетических конструкций
WO2017033963A1 (ja) * 2015-08-26 2017-03-02 株式会社スタージェン 細胞内ａｔｐ増強剤
WO2020140730A1 (zh) * 2018-12-30 2020-07-09 广州君赫生物科技有限公司 硫鸟嘌呤在制备治疗adsl缺陷症药物中应用
EP3797764A1 (de) 2019-09-27 2021-03-31 Janusz Chupty Contissi Pharmakologische zusammensetzung zur behandlung von dysfunktion des nervengewebes, insbesondere der viralen latenz, und die verwendung von substanzen der gruppe j05 atc zur behandlung von dysfunktion des nervengewebes, insbesondere der viralen latenz
US11311565B2 (en) 2020-06-25 2022-04-26 Celagenex Research (India) Pvt. Ltd. Synergistic nutritional compositions for promoting axonal regeneration
US20250127787A1 (en) * 2021-09-28 2025-04-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating peripheral neuropathy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3808027A (en) 1972-03-29 1974-04-30 Du Pont Silica surfaced films
US4341868A (en) * 1978-08-18 1982-07-27 Kyowa Hakko Kogyo Co., Ltd. Method and test composition for the determination of the substrate for xanthine oxidase
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
WO1988009335A1 (en) 1987-05-26 1988-12-01 Paul Gordon Polymorphs of inosine and methods of making and using them
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
FI921092A7 (fi) 1989-09-15 1992-03-13 Gensia Pharma Menetelmä neurodegeneratiivisten tilojen hoitamiseksi
JPH05506842A (ja) * 1989-09-15 1993-10-07 ジェンシア・ファーマシュウティカルズ・インコーポレイテッド 神経変性状態の処置方法
RU1755583C (ru) * 1990-10-31 1994-08-30 ВНИИ генетики и селекции промышленных микроорганизмов Способ получения инозина
FR2692784B1 (fr) * 1992-06-24 1995-06-30 Pf Medicament Utilisation de la guanosine, de ses precurseurs et ses derives pour la fabrication de medicaments destines a traiter les deficits fonctionnels cerebraux.
US5483130A (en) * 1992-09-09 1996-01-09 Axelerator, Inc. Structure for accelerating heavy ions with uniformly spaced quadrupole focusing (USQF)
US5422343A (en) * 1992-12-21 1995-06-06 Otsuka Pharmaceutical Factory, Inc. Prophylactic and therapeutic composition for MRSA infection
US5438130A (en) * 1993-01-15 1995-08-01 Cambridge Neuroscience, Inc. Fucosylated guanosine disulfates as excitatory amino acid antagonists
RU2063753C1 (ru) 1993-04-22 1996-07-20 Василий Владимирович Афанасьев Способ лечения экстрапирамидного синдрома при остром отравлении галоперидолом
CN1128951A (zh) * 1993-08-13 1996-08-14 生化学工业株式会社 治疗神经元疾病的药物
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
RU2098085C1 (ru) * 1994-04-07 1997-12-10 Николай Васильевич Карсанов Антигипоксическое средство
US5447939A (en) * 1994-07-25 1995-09-05 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
AU4808997A (en) * 1996-09-30 1998-04-24 Brigham And Women's Hospital Methods and compounds for treatment of abnormal uterine bleeding
US6440455B1 (en) * 1997-09-02 2002-08-27 Children's Medical Center Corporation Methods for modulating the axonal outgrowth of central nervous system neurons
US6855690B2 (en) * 2000-06-01 2005-02-15 Children's Medical Center Corporation Methods and compositions for treating ocular disorders
GB2379797A (en) * 2001-09-15 2003-03-19 Zarlink Semiconductor Ab Surface Emitting Laser

Also Published As

Publication number Publication date
JP2001516695A (ja) 2001-10-02
US20070213294A1 (en) 2007-09-13
EP1466606A3 (de) 2004-11-24
US6440455B1 (en) 2002-08-27
US20040014710A1 (en) 2004-01-22
RU2000108443A (ru) 2002-02-10
KR100564789B1 (ko) 2006-03-28
RU2212241C2 (ru) 2003-09-20
EP1009412A1 (de) 2000-06-21
AU6656898A (en) 1999-03-22
US20050277614A1 (en) 2005-12-15
NZ503073A (en) 2002-11-26
CA2302156C (en) 2006-11-21
US6551612B2 (en) 2003-04-22
EP1009412B1 (de) 2004-07-28
EP1466606A2 (de) 2004-10-13
US20020137721A1 (en) 2002-09-26
US20020128223A1 (en) 2002-09-12
JP4601816B2 (ja) 2010-12-22
CA2302156A1 (en) 1999-03-11
US20020042390A1 (en) 2002-04-11
AU748961B2 (en) 2002-06-13
KR20010023578A (ko) 2001-03-26
WO1999011274A1 (en) 1999-03-11
US7338666B2 (en) 2008-03-04
CN1286632A (zh) 2001-03-07
DE69825292T2 (de) 2005-05-25
DE69825292D1 (de) 2004-09-02
US7935680B2 (en) 2011-05-03
HK1029916A1 (en) 2001-04-20
US20020055484A1 (en) 2002-05-09

Similar Documents

Publication Publication Date Title
DE69825292D1 (de) Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
DE69331605D1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
ATE256475T1 (de) Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten
ATE127804T1 (de) Pharmazeutische verbindungen.
ATE83659T1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ATE94069T1 (de) Verwendung von physiologisch wirksamen substanzen zur herstellung von medikamenten fuer gehirn- und nervenerkrankungen.
IL104006A (en) Azaheterocyclylmethyl-chromans their preparation and pharmaceutical compositions containing them
DE69739792D1 (de) Verfahren zur Behandlung von Augenerkrankungen
HU0301601D0 (en) Bis(n-substituted)-staurosporine derivatives, their use and pharmaceutical composition containing thereof
WO1997003188A3 (de) Verwendung von mp52 oder mp121 zur behandlung und prävention von erkrankungen des nervensystems
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
ATE128865T1 (de) Verwendung von l-deprenyl zur herstellung eines arzneimittels zur behandlung der cushing's- krankheit.
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
ATE94764T1 (de) Nasal applizierbares arzneimittel, verfahren zu seiner herstellung und seine verwendung.
NO944339L (no) Melatoninderivater for anvendelse ved behandling av sövnforstyrrelser
GR3019774T3 (en) Piperidylmethyl substituted chroman derivatives as agents for the treatment of diseases of the central nervous system
AU4333893A (en) Use of guanosine and its precursors and derivatives in the manufacture of drugs for the treatment of brain dysfunction
DE59304087D1 (de) Placentaextrakt und Verfahren zu seiner Herstellung
EP0495998A4 (de)
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
DE69424415D1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
DE69516602D1 (de) Verwendung von Bifemelan zur Herstellung eines Arzneimittels zur Behandlung der Hyperkinesie
IT1251993B (it) Composizioni farmaceutiche ad uso orale,a base di esteri di gangliosidi,per il trattamento di neuropatie del sistema nervoso periferico
UA10259A (uk) Протинабряковий лікарський препарат "нейрополіосм"

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties